$NVS News

Novartis AG Reports Q3 2026 Financial Results and Raises Full-Year Core Operating Income Guidance

Novartis raises annual profit outlook after strong Q3 sales growth

Novartis: Q3 Earnings Snapshot

Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance

Novartis (SWX:NOVN) Gains Fresh Trial Focus, Is The Good News Already Priced In?

Novartis (SWX:NOVN) Advances Two Key Growth Drugs With New Late Stage Data

Novartis Reports Lower Relapse Rates and No Hy’s Law Cases in Phase 3 Remibrutinib MS Trials

Novartis: Strong Drug Growth Faces A Tougher Test As Patent Losses And Pipeline Setbacks Mount

AI Bubble Fears Trigger a Surprising Shift to Swiss Stocks

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript

Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis - Slideshow

Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile

Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis

Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence

Novartis Announces Its Data From Phase III NATALEE Study Demonstrates Kisqali Eliminates Risk Of Death By ~20% In Patients With Stage II And III HR+/Her2- Early Breast Cancer

Novartis (SWX:NOVN) Stock May Trade Below Fair Value Following Cosentyx Approval

Novartis (SWX:NOVN) Wins EU Approval For Cosentyx In Polymyalgia Rheumatica

Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

Novartis (NVS) Grew Sales Again as Entresto Fell 50%, Can Remibrutinib Carry It?